Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

CDC Provisionally Recommends Pfizer’s Abrysvo for Maternal Immunization Against RSV

Fineline Cube Sep 25, 2023

The US Centers for Disease Control and Prevention (CDC) has issued a provisional recommendation for...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention

Fineline Cube Sep 25, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US...

Company Drug

MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study

Fineline Cube Sep 25, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...

Company Drug

Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors

Fineline Cube Sep 25, 2023

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...

Company

Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials

Fineline Cube Sep 25, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing...

Company

3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales

Fineline Cube Sep 25, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first...

Company Medical Device

Acotec Scientific Holdings Receives Japanese Marketing Approval for Peripheral Support Catheter Vericor

Fineline Cube Sep 25, 2023

Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...

Company Deals

Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development

Fineline Cube Sep 25, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation...

Company Deals

Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing

Fineline Cube Sep 25, 2023

Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised...

Company Drug

CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge

Fineline Cube Sep 25, 2023

The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences...

Company Deals

Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia

Fineline Cube Sep 25, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license...

Company Deals

I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination

Fineline Cube Sep 25, 2023

China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises...

Company Drug

Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China

Fineline Cube Sep 22, 2023

France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval...

Company Legal / IP Policy / Regulatory

EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare

Fineline Cube Sep 22, 2023

The EU Chamber of Commerce in China has released its bi-annual “European Business in China...

Company Legal / IP

Eli Lilly Sues US Sellers of Counterfeit Mounjaro Products

Fineline Cube Sep 22, 2023

Pharmaceutical giant Eli Lilly (NYSE: LLY) has filed a lawsuit in the United States against...

Company Deals

Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million

Fineline Cube Sep 22, 2023

Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk...

Company

MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions

Fineline Cube Sep 22, 2023

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for...

Company R&D

Amgen Launches Global Collaboration Network to Advance Oncology Research

Fineline Cube Sep 22, 2023

Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its...

Company Deals

Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies

Fineline Cube Sep 22, 2023

Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with...

Company Drug

Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Sep 22, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...

Posts pagination

1 … 521 522 523 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.